Susceptibility to recombinant SARS‐CoV ‐2 spike protein entry in the lungs of high‐fat diet‐induced obese mice
The FASEB Journal · 2024
DOI: 10.1096/fj.202301864rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Koro Gotoh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Japan. Hauptthemen laut MEDLINE: COVID-19, Diet, High-Fat, Lung, Obesity. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Grants-in-Aid for Scientific Research (21K11596 to KG and 23K09671 to HS).
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Obesity is a major risk factor for the development of COVID‐19. Angiotensin‐converting enzyme 2 (ACE2) is an essential receptor for cell entry of SARS‐CoV‐2. The receptor‐binding domain of the S1 subunit (S1‐RBD protein) in the SARS‐CoV‐2 spike glycoprotein binds to ACE2 on host cells, through which the virus enters several organs, including the lungs. Considering these findings, recombinant ACE2 might be utilized as a decoy protein to attenuate SARS‐CoV‐2 infection. Here, we examined whether obesity increases ACE2 expression in the lungs and whether recombinant ACE2 administration diminishes the entry of S1‐RBD protein into lung cells. We observed that high‐fat diet‐induced obesity promoted ACE2 expression in the lungs by increasing serum levels of LPS derived from the intestine. S1‐RBD protein entered the lungs specifically through ACE2 expressed in host lungs and that the administration of recombinant ACE2 attenuated this entry. We conclude that obesity makes hosts susceptible to recombinant SARS‐CoV‐2 spike proteins due to elevated ACE2 expression in lungs, and this model of administering S1‐RBD protein can be applied to new COVID‐19 treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Japan.
- ARK Resource Co, Ltd, Kumamoto, Japan.
ORCID-Profile: Koro Gotoh, Kentaro Sada, Shotaro Miyamoto, Yuichi Yoshida, Takayuki Masaki, Toshiaki Kawabe, Hirotaka Shibata
Förderung
- Grants-in-Aid for Scientific Research (21K11596 to KG and 23K09671 to HS)
Zitieren
APA
Gotoh, K., Satoh, F., Uesugi, H., Noguchi, T., Matsuda, N., Sada, K., Miyamoto, S., Ozeki, Y., Yoshida, Y., Okamoto, M., Masaki, T., Kawabe, T., & Shibata, H. (2024). Susceptibility to recombinant SARS‐CoV ‐2 spike protein entry in the lungs of high‐fat diet‐induced obese mice. The FASEB Journal. https://doi.org/10.1096/fj.202301864rr
Vancouver
Gotoh K, Satoh F, Uesugi H, Noguchi T, Matsuda N, Sada K, et al. Susceptibility to recombinant SARS‐CoV ‐2 spike protein entry in the lungs of high‐fat diet‐induced obese mice. The FASEB Journal. 2024. doi:10.1096/fj.202301864rr
BibTeX
@article{Gotoh2024,
author = {Gotoh, Koro and Satoh, Fumiko and Uesugi, Honami and Noguchi, Takaaki and Matsuda, Naoki and Sada, Kentaro and Miyamoto, Shotaro and Ozeki, Yoshinori and Yoshida, Yuichi and Okamoto, Mitsuhiro and Masaki, Takayuki and Kawabe, Toshiaki and Shibata, Hirotaka},
title = {Susceptibility to recombinant SARS‐CoV ‐2 spike protein entry in the lungs of high‐fat diet‐induced obese mice},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202301864rr}
}
EUVIMED